Google
NVCR 株価分析 — NOVOCURE LTD (Healthcare >> Medical Devices)
NVCR に関するよくある質問
NVCRのROE（自己資本利益率）は？
NOVOCURE LTDのROEは-43.94%です。
NVCRの配当利回りは？
NOVOCURE LTDの配当利回りは0.00%です。
NVCRの品質スコア（Quality Score）は？
当社のAIはNVCRの総合財務品質を100点中46点と評価しています。収益性・成長性・負債・利益の安定性に基づく評価です。
NVCRは今が買い時ですか？
当社AIのタイミングスコアは100点中56点で、テクニカル指標とモメンタムから見た現在価格の相対的な魅力度を示します。
NVCRはどのセクターに属しますか？
NOVOCURE LTDはHealthcare >> Medical Devicesセクターに分類されます（NASDAQ市場）
NVCR AI Analysis Summary
Our AI summary for NVCR: NOVOCURE LTD (NASDAQ), Healthcare >> Medical Devices sector. The stock currently trades at a P/E of 0.00, ROE of -43.94%, a dividend yield of 0.00%. Its financial Quality Score stands at 46/100 — fundamentals below the market average. The AI Timing Score is 56/100 — technical signals are mixed; watch for a clearer trend. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 14.84
Price
-0.39
(-2.56%)
Day Change
|
|
|---|
NVCR, ファンダメンタルスコアはnot good ( ファンダメンタル = 46) そして テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROEが低い
ROAが低い
平均ROEが低い
ROEが昨年度比で低い
Last-year ROA is lower than last-2-years ROA.
NPMが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not good , financial health is not good , and ability to make profit is ok , ...
| Deepscope 分析 |
|
45% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 91 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 14.84 |
| PBV / Sector |
5.25 / -101.57
|
| Earning Per Share | -1.24 |
| PE / Sector |
N/A / 31.23
|
| PEG or PE/Growth / Sector |
N/A / 0.40
|
| Average 1M Daily Value |
30.39 M
GREAT
|
| Average 1W Daily Value |
22.90 M
GREAT
|
| Timing Factors |
|
14% |
| Financial Health |
|
43% |
| ポイントになる統計 |
|
60% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-08-01 08:00:15 |
| Symbol | NVCR |
| Name | NOVOCURE LTD |
| Sector | Healthcare >> Medical Devices |
| Market | NASDAQ |
| Listed Shares | 116.45 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 1,773.47 / 20,104.97 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: Neuhofstrasse 21, Baar, Switzerland, 6340
Phone: 44 15 3475 6700
Website: https://www.novocure.com
Employees: 1,605
Sector: Healthcare >> Medical Devices
Description: NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax. The company also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Medical Devices
Click a bubble to view stock details · Bubble size represents market capitalization share
